PDCD1 and neoplasm: Measurement of WBC counts over time by hematology analyzer found that only the combination of JQ1 + anti-PD1 significantly reduced tumor burden and, as expected from the ex vivo proliferation assays, anti-PD1 alone had no effect (Fig. 4B).